Albis® is developed by Yonsei University.

What development phase is Albis® in?

Albis® is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Albis®

Yonsei University · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Albis®
Sponsor	Yonsei University
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy (PHASE4)
The Safety and Efficacy of Albis®: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Albis® CI brief — competitive landscape report
Albis® updates RSS · CI watch RSS
Yonsei University portfolio CI